PD1 and/or LAG3 binders
The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
1. A method for inhibiting PD1 from binding to PD-L1 and/or PD-L2 comprising contacting the PD1 with a PD1 binder comprising one or more immunoglobulin single variable domains (ISVDs) that bind PD1, each ISVD comprising (i) a CDR1 comprising the amino acid sequence IHAMG (SEQ ID NO: 3) or GSIASIHAMG (SEQ ID NO: 6); a CDR2 comprising the amino acid sequence VITXSGGITYYADSVKG (SEQ ID NO: 4) or VITXSGGITY (SEQ ID NO: 7); and a CDR3 comprising the amino acid sequence DKHQSSXYDY (SEQ ID NO: 5), and (ii) substitution of a leucine at position 11 with valine and a substitution of a isoleucine at position 89 with leucine, wherein the positions are numbered according to Kabat, and optionally, further comprising a half-life extender and/or a C-terminal extender to a subject, and wherein the PD1 binder may optionally be in association with a further therapeutic agent.
2. A method for enhancing an immune response in a subject comprising administering an effective amount of a PD1 binder comprising one or more immunoglobulin single variable domains (ISVDs) that bind PD1, each ISVD comprising (i) a CDR1 comprising the amino acid sequence IHAMG (SEQ ID NO: 3) or GSIASIHAMG (SEQ ID NO: 6); a CDR2 comprising the amino acid sequence VITXSGGITYYADSVKG (SEQ ID NO: 4) or VITXSGGITY (SEQ ID NO: 7); and a CDR3 comprising the amino acid sequence DKHQSSXYDY (SEQ ID NO: 5), and (ii) a substitution of a leucine at position 11 with valine and a substitution of a isoleucine at position 89 with leucine, wherein the positions are numbered according to Kabat, and optionally, further comprising a half-life extender and/or a C-terminal extender to a subject, and wherein the PD1 binder may optionally be in association with a further therapeutic agent.
3. A method for treating cancer or an infectious disease in a human subject comprising administering an effective amount of a PD1 binder comprising one or more immunoglobulin single variable domains (ISVDs) that bind PD1, each ISVD comprising (i) a CDR1 comprising the amino acid sequence IHAMG (SEQ ID NO: 3) or GSIASIHAMG (SEQ ID NO: 6); a CDR2 comprising the amino acid sequence VITXSGGITYYADSVKG (SEQ ID NO: 4) or VITXSGGITY (SEQ ID NO: 7); and a CDR3 comprising the amino acid sequence DKHQSSXYDY (SEQ ID NO: 5), and (ii) a substitution of a leucine at position 11 with valine and a substitution of a isoleucine at position 89 with leucine, wherein the positions are numbered according to Kabat, and optionally, further comprising a half-life extender and/or a C-terminal extender to a subject, and wherein the PD1 binder may optionally be in association with a further therapeutic agent.
4. The method claim 3 wherein the cancer is metastatic cancer, a solid tumor, a hematologic cancer, leukemia, lymphoma, osteosarcoma, rhabdomyosarcoma, neuroblastoma, kidney cancer, leukemia, renal transitional cell cancer, bladder cancer, Wilm's cancer, ovarian cancer, pancreatic cancer, breast cancer, prostate cancer, bone cancer, lung cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, cervical cancer, synovial sarcoma, head and neck cancer, squamous cell carcinoma, multiple myeloma, renal cell cancer, retinoblastoma, hepatoblastoma, hepatocellular carcinoma, melanoma, rhabdoid tumor of the kidney, Ewing's sarcoma, chondrosarcoma, brain cancer, glioblastoma, meningioma, pituitary adenoma, vestibular schwannoma, a primitive neuroectodermal tumor, medulloblastoma, astrocytoma, anaplastic astrocytoma, oligodendroglioma, ependymoma, choroid plexus papilloma, polycythemia vera, thrombocythemia, idiopathic myelfibrosis, soft tissue sarcoma, thyroid cancer, endometrial cancer, carcinoid cancer or liver cancer, breast cancer or gastric cancer.
5. The method claim 3 wherein the infectious disease is a bacterial infection, a viral infection or a fungal infection.
6. The method of claim 3 wherein the subject is administered a further therapeutic agent or a therapeutic procedure in association with the binder.
7. The method of claim 3 , wherein each ISVD that binds PD1 independently comprises an amino acid sequence selected from the group consisting of
(SEQ ID NO: 57)
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTV
SS;
(SEQ ID NO: 99)
EVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTV
SS;
(amino acids 1-119 of SEQ ID NO: 101)
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTV
SS;
(SEQ ID NO: 103)
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITVSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTV
SS;
(SEQ ID NO: 104)
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITVSGGITYYADSVKGRFTISRDQSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTV
SS;
and
(SEQ ID NO: 105)
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITVSGGITYYADSVKGRFTISRDPSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTV
SS.
8. The method of claim 3 , wherein the PD1 binder further includes a C-terminal extender, which is an alanine residue.
9. The method of claim 3 , wherein the PD1 binder further includes a half-life extender comprising an ISVD that binds human serum albumin wherein the ISVD comprises a CDR1 comprising the amino acid sequence GFTFSSFGMS (SEQ ID NO: 60) or SFGMS (SEQ ID NO:151); a CDR2 comprising the amino acid sequence SISGSGSDTLYADSVKG (SEQ ID NO: 61) or SISGSGSDTL (SEQ ID NO:152); and a CDR3 comprising the amino acid sequence GGSLSR (SEQ ID NO: 62).
10. The method of claim 3 , wherein the PD1 binder further includes a half-life extender comprising an ISVD that binds human serum albumin wherein the ISVD comprises the amino acid sequence
(SEQ ID NO: 142)
EVQLVESGGGVVQPGNSLRLSCAASGETFSSFGMSWVRQ
APGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTT
LYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS.
11. The method of claim 3 , wherein the PD1 binder comprises (i) an ISVD that binds PD1 comprising the amino acid sequence DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKN TVYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS (SEQ ID NO:57); (ii) a half-life extender comprising an ISVD that binds human serum albumin and comprises the amino acid sequence EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKT TLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS (SEQ ID NO: 142); and, (iii) a C-terminal extender comprising an alanine residue.
12. The method of claim 11 , wherein the PD1 binder further includes a polypeptide linker that links the C-terminus of the ISVD that binds PD1 to the N-terminus of the ISVD that binds human serum albumin, wherein the polypeptide linker comprises the amino acid sequence set forth in SEQ ID NO: 58.
13. The method of claim 2 , wherein each ISVD that binds PD1 independently comprises an amino acid sequence selected from the group consisting of
(SEQ ID NO: 57)
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTV
SS;
(SEQ ID NO: 99)
EVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTV
SS;
(amino acids 1-119 of SEQ ID NO: 101)
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTV
SS;
(SEQ ID NO: 103)
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITVSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTV
SS;
(SEQ ID NO: 104)
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITVSGGITYYADSVKGRFTISRDQSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTV
SS;
and
(SEQ ID NO: 105)
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQ
APGKEREFVAVITVSGGITYYADSVKGRFTISRDPSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTV
SS.
14. The method of claim 2 , wherein the PD1 binder further includes a C-terminal extender, which is an alanine residue.
15. The method of claim 2 , wherein the PD1 binder further includes a half-life extender comprising an ISVD that binds human serum albumin wherein the ISVD comprises a CDR1 comprising the amino acid sequence GFTFSSFGMS (SEQ ID NO: 60) or SFGMS (SEQ ID NO:151); a CDR2 comprising the amino acid sequence SISGSGSDTLYADSVKG (SEQ ID NO: 61) or SISGSGSDTL (SEQ ID NO:152); and a CDR3 comprising the amino acid sequence GGSLSR (SEQ ID NO: 62).
16. The method of claim 2 , wherein the PD1 binder further includes a half-life extender comprising an ISVD that binds human serum albumin wherein the ISVD comprises the amino acid sequence
(SEQ ID NO: 142)
EVQLVESGGGVVQPGNSLRLSCAASGETFSSFGMSWVRQ
APGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTT
LYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS.
17. The method of claim 2 , wherein the PD1 binder comprises (i) an ISVD that binds PD1 comprising the amino acid sequence DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKN TVYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS (SEQ ID NO:57); (ii) a half-life extender comprising an ISVD that binds human serum albumin and comprises the amino acid sequence EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKT TLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS (SEQ ID NO: 142); and, (iii) a C-terminal extender comprising an alanine residue.
18. The method of claim 17 , wherein the PD1 binder further includes a polypeptide linker that links the C-terminus of the ISVD that binds PD1 to the N-terminus of the ISVD that binds human serum albumin, wherein the polypeptide linker comprises the amino acid sequence set forth in SEQ ID NO: 58.